

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 January 2018 (04.01.2018)



(10) International Publication Number
WO 2018/002760 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 25/16 (2006.01)
A61K 31/437 (2006.01) A61P 25/18 (2006.01)
A61P 25/00 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:

PCT/IB2017/053565

(22) International Filing Date:

15 June 2017 (15.06.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/357,624 01 July 2016 (01.07.2016) US
62/372,421 09 August 2016 (09.08.2016) US

(71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street,
New York, NY 10017 (US).

(72) Inventors: ZHANG, Lei; 75 Bourne Street, Auburndale,
MA 02466 (US). BUTLER, Christopher Ryan; 121
Spring Lane, Canton, MA 02021 (US). BECK, Elizabeth
Mary; 27A Botley Road, Oxford, Oxfordshire OX2 0BN
(GB). BRODNEY, Michael Aaron; 100 Upland Ave.,
Newton, MA 02461 (US). BROWN, Matthew Frank;
443 Wheeler Road, Stonington, CT 06378 (US). MCAL-
LISTER, Laura Ann; 428 Massachusetts Ave., Apt. 6, Ar-
lington, MA 02474 (US). LACHAPPELLE, Erik Alphie;
69 Richard Brown Drive, Uncasville, CT 06382 (US). GIL-
BERT, Adam Matthew; 178 Denison Drive, Guilford, CT
06437 (US).

(74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 East 42nd
Street, MS 235/9/S20, New York, NY 10017 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES FOR TREATING NEUROLOGICAL AND NEURODEGEN-
ERATIVE DISEASES



(57) Abstract: The present invention provides, in part, compounds of Formula (I); or an *N*-oxide thereof, or a pharmaceutically acceptable salt of the compound or the *N*-oxide, wherein: R¹, R², L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, *N*-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.



WO 2018/002760 A1